Systemic Treatments for the Management of Prurigo Nodularis
A dermatology expert provides comprehensive insights into prurigo nodularis, discussing its disproportionate impact on middle-aged adults and immunocompromised individuals, the evolution of treatment from traditional dermatologic therapies to FDA-approved biologics (dupilumab and nemolizumab), and the importance of addressing both the physical symptoms and psychological burden while considering patient-specific factors such as comorbidities in treatment selection.
EP. 1: Understanding Patient Comorbidities and Burden of Disease in Prurigo Nodularis
December 20th 2024A panelist discusses how prurigo nodularis is a chronic inflammatory skin condition that disproportionately affects middle-aged adults and those with immune disorders, causing intensely pruritic nodules that significantly impact quality of life through both physical discomfort and psychological distress.
EP. 2: Advances in Systemic Treatment Options for Prurigo Nodularis
December 20th 2024A panelist discusses how the treatment landscape for prurigo nodularis (PN) has evolved from primarily using topical therapies and off-label systemic medications to incorporating FDA-approved targeted biologics such as dupilumab and nemolizumab, which have demonstrated significant efficacy in reducing both the itchiness and nodular lesions.
